EC Gynaecology

Background: Coronavirus disease 2019 (COVID-19) acquired pneumonia is the leading cause of death worldwide. Hospital mortality among patients with COVID-19 infection is still high. Medicinal plant has been used for thousands of years for treating respiratory infections. Nowadays many complementary therapies are offered for patients with covid-19 pneumonia, it is not very clear whether herbal supplements are suitable therapy for this type of pneumonia.

Aim: Evaluation of the efficacy of the herbal supplementary mixture of volatile oils of Rhus coriaria, thyme and star anise (CovETS) in cases of COVID-19 acquired pneumonia.

Subjects and Methods: A prospective controlled clinical study during the period of 3 months from 20 march to 20 June 2020, conducted on 88 patients assigned to one of two groups, the control (Non-CovETS) group (43 patients) received conventional WHO anti Covid-19 protocol alone and the study (CovETS) group (45 patients) received a combination of the same conventional WHO protocol and the covets.

Results: A statistically significant improvement of the CovETS group (patients who received both who protocol and herbal supplements), regarding time of clinical stability (p = 0.001), hospital stay (p = 0.001), mechanical ventilation (p = 0.045), post covid syndrome (p = 0.037) and hospital mortality (p = 0.029) of the COVID 19 pneumonic patients.

A highly statistically significant improvement in the success and mortality rates among the CovETS than the non-CovETS groups of the pneumonic high-risk patients.

Conclusion: CovETS improved the clinical profile and mortality rates of the covid-19 pneumonia patients.

Keywords: COVID-19 Related Pneumonia; Herbs; CovETS

1. Guan WJ., et al. “Clinical characteristics of coronavirus disease 2019 in China”. New England Journal of Medicine18 (2020): 1708 -1720.
2. Ma L and Yao L. “Antiviral effects of plant derived essential oils and their components: an updated review”. Molecules11 (2020): 2627.
3. Silveira D., et al. “Covid-19 is there evidence for the use of herbal medicines as adjuvant symptomatic therapy?” Frontiers in Pharmacology 11 (2020): 581840.
4. Korkmaz H. “Could sumac be effective on covid-19 treatment?” Journal of Medicinal Food 6 (2021): 563-568.
5. Lin YM., et al. “Antiviral activities of bioflavonoids”. Planta Medica 2 (1999): 120-125.
6. Ocana A and Reglero G. “Effects of thyme extract oils from (Thymus vulgaris, Thymus zygis and Thymus hyemalis) on cytokine production and gene expression of Oxldl-stimulated THP-1 macrophages”. Journal of Obesity (2012): 104708.
7. Bukovska A., et al. “Effects of a combination of thyme and organo essential oils on TNBS -induced colitis in mice”. Mediators of Inflammation (2007): 23296.
8. Park SH., et al. “Protective activity of ethanol extract of the fruits of Illicium verum against atherogenesis in apolipoprotein eknockout mice”. BMC Complementary and Alternative Medicine 15 (2015): 232.
9. Edessy PM, And Tawfik PR. “Edessy-Tawfic COVID-19 Supplements (Covets)”. Ecronicon Open Access Scientific Publication: Online Publications: Medical. Academia Letters (2021): 3266.
10. Reichling J. “Antiviral and virucidal properties of essential oils and isolated compounds-a scientific approach”. Planta Medica 8 (2022): 587-603.
11. Parsania M., et al. “Evaluation of antiviral effects of sumac (Rhus coriaria) fruit extract on acyclovir resistant herpes simplex virus type 1”. Medical Sciences1 (2017): 1-8.
12. Gharabolagh AF., et al. “Effects of Rhus coriaria (sumac) extract on hepatitis B virus replication and Hbs Ag secretion”. Journal of Reports in Pharmaceutical Sciences1 (2018): 100-107.
13. Shereif YE., et al. “Phytochemical of Rhus spp as potential inhibitors of the SARS-Cov-2 main protease: molecular docking and drug-likeness study”. Evidence-Based Complementary and Alternative Medicine (2021): 8814890.
14. Im WK., et al. “Fisetin-Rich extracts of Rhus vernicflua stocks improve blood flow rates in mice fed both normal and high fat diets”. Journal of Medicinal Food 2 (2016): 120-126.
15. Lagunas-Rangel FA and Chavez-Valencia V. “High IL-6⁄IFN-Y ratio could be associated with severe disease in covid-19 patients”. Journal of Medical Virology 10 (2020): 1789-1790.
16. Xiong Y., et al. “Clinical and high-resolution CT features of the covid-19 infection: comparison of the initial and follow up changes”. Investigative Radiology 6 (2020): 332-339.
17. Oliviera M., et al. “Evaluation of thyme extract effects in human normal bronchial and tracheal epithelial cell lines and in human lung cancer cell line". Chemico-Biological Interactions 256 (2016): 125-133.
18. Kang P., et al. “Anti-inflammatory effects of anethole in lipopolysaccharide induced acute lung injury in mice”. Life Science24 (2013): 955-961.
19. Sung YY., et al. “Illicium verum extract and transe-anethole attenuate ovalbumin - induced airway inflammation via enhancement of Foxp3+ regulatory T cells and inhibition of Th2 cytokines in mice”. Mediators of Inflammation (2017): 7506808.
20. Zhan H., et al. “Diagnostic value of D-dimer in covid-19: a meta analysis and meta regression”. Clinical and Applied Thrombosis/Hemostasis 27 (2021): 10760296211010976.
21. World Health Organization. Coronavirus disease (COVID-19) pandemic (2021).
22. COVID Live Update, 18^th May 2021.
23. Matthieu Wargny and Louis Potier. “Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study”. Diabetologia4 (2021): 778-794.
24. Fei Xia., et al. “COVID-19 patients with hypertension are at potential risk of worsened organ injury”. Scientific Reports 11 (2021): 3779.
25. MA de Graaf., et al. “Short-term outpatient follow-up of COVID-19 patients: A multidisciplinary approach”. Eclinicalmedicine 32 (2021): 100731.